Low Progesterone Symptoms: What It Means and When It Matters

• Progesterone is the dominant hormone of the second half of your cycle (the luteal phase). It is only produced after ovulation, by the corpus luteum.
• 'Low progesterone' is usually a sign of a deeper issue, most often anovulation (no ovulation), which is what actually needs treating.
• Most symptoms blamed on low progesterone, including PMS, anxiety, weight gain, and hair loss, are not caused by progesterone deficiency in cycling women.
• Progesterone is genuinely essential in IVF luteal support, certain pregnancy bleeding situations, and as part of menopause hormone therapy when you still have a uterus.
• Test correctly: a serum progesterone drawn about 7 days before your next expected period (the mid-luteal peak), not on a fixed day.
• Over-the-counter progesterone creams have unreliable dosing and weak evidence; FOGSI and the Indian Medical Association caution against unsupervised use.

Progesterone is produced mainly by the corpus luteum, a temporary gland that forms in the ovary after ovulation from the follicle that released the egg. Its production peaks about 7 to 8 days after ovulation and stays elevated for roughly 10 to 14 days. If you don't conceive, the corpus luteum regresses, progesterone falls sharply, and that hormonal withdrawal triggers your period. If you do conceive, the corpus luteum keeps producing progesterone for the first 8 to 10 weeks until the placenta takes over.

Its core jobs are reproductive. After What Ovulation Actually Means, progesterone transforms the estrogen-primed uterine lining from a proliferative state into a secretory one, ready to receive an embryo. It maintains that lining in early pregnancy, thickens cervical mucus, and suppresses further ovulation. Together these create the environment needed for implantation and early pregnancy.

Progesterone also acts beyond the uterus. It raises your basal body temperature by roughly 0.3 to 0.5 degrees Celsius, which is why basal body temperature charting can confirm ovulation after the fact. Through its metabolite allopregnanolone, which acts on GABA receptors much like a mild sedative, it has calming effects; this is why some women feel sleepier or calmer in the luteal phase and why oral progesterone taken at night often improves sleep.

What matters most is the balance between estrogen and progesterone, not the absolute level of either. Estrogen dominates the first half of the cycle, both rise after ovulation, and the ratio shifts as the luteal phase progresses. Many symptoms blamed on 'low progesterone' are really symptoms of anovulatory cycles, where progesterone never rises because no corpus luteum formed. Supplementing progesterone without ovulation does not restore normal cycle physiology; it just creates a different artificial pattern.

Levels also vary hugely across the cycle and across life. In the first half of the cycle they are very low (usually under 1 ng/mL). After ovulation they rise to a mid-luteal peak of about 5 to 20 ng/mL. In pregnancy they climb progressively; after menopause, ovarian production essentially stops. This is why any blood test must specify the cycle phase, and why a single random reading without context is often uninterpretable.

Finally, synthetic progestins are not the same as natural progesterone. Medroxyprogesterone, norethindrone, dydrogesterone, and levonorgestrel are used in contraception, hormone therapy, and gynaecological treatment, but differ in receptor binding and side-effect profiles. The choice between micronised natural progesterone and a synthetic progestin depends on the clinical purpose, and outcomes can differ depending on which is used.

Genuine, clinically meaningful low progesterone occurs in a fairly narrow set of situations. The most common is anovulation: if you don't ovulate, no corpus luteum forms and progesterone never rises. This is the typical pattern in PCOS, in hypothalamic amenorrhoea, in perimenopause with skipped ovulation, and in postpartum or post-pill recovery. Here the real problem isn't 'low progesterone' as such; it's the anovulation behind it, and treatment targets that cause.

Luteal phase defect (LPD) is a more specific situation in which ovulation happens but the corpus luteum makes too little progesterone or for too short a time, classically a luteal phase under 10 days. Its significance is debated; the American Society for Reproductive Medicine (ASRM) notes the diagnosis is poorly reproducible and that progesterone supplementation doesn't reliably improve outcomes in isolated LPD. Even so, it may matter in some recurrent pregnancy loss, and luteal support is standard in assisted reproduction. We cover this in detail in luteal phase defect.

IVF and other ART cycles routinely use progesterone in the luteal phase because the drugs used to stimulate the ovaries disrupt normal corpus luteum function. Vaginal progesterone (Cygest, Crinone, Susten) at 200 to 800 mg daily, intramuscular progesterone in oil, or oral dydrogesterone are commonly used, usually continued until 10 to 12 weeks. This is an evidence-based use where the cycle genuinely needs support.

Menopausal hormone therapy (MHT) for a woman with an intact uterus must include a progestogen alongside estrogen. Unopposed estrogen raises the risk of endometrial hyperplasia and cancer; adding a progestogen, whether cyclic, continuous, or via the Mirena IUD, protects the lining. This is one of the clearest indications for a progestogen in current practice, recommended by ACOG, NICE, and the Indian Menopause Society.

In short, real low progesterone is almost always a downstream sign. The useful question is rarely 'is my progesterone low?' but 'why isn't my body ovulating and producing it normally?'

A long list of symptoms gets pinned on low progesterone in wellness marketing and even some clinics. Some links have reasonable evidence; many are overstated. Sorting them out helps you know when supplementing progesterone might help and when it simply won't touch the real cause.

PMS and PMDD are often blamed on low progesterone, but the evidence for deficiency is weak. Most studies find women with PMS have normal progesterone; the symptoms seem to come from how the brain responds to normal cyclic hormone shifts, especially via allopregnanolone and GABA receptors. Progesterone supplementation generally doesn't beat placebo for PMS. For PMDD, SSRIs (continuous or luteal-phase only) have much stronger evidence.

Anxiety and insomnia get linked to progesterone because allopregnanolone is calming. Some women do report better sleep and less anxiety with oral micronised progesterone at night, which is well documented in menopause care. But for non-menopausal women, evidence for progesterone as a primary treatment is limited, and first-line approaches (cognitive behavioural therapy, sleep hygiene, and SSRIs where indicated) are usually tried first.

Heavy menstrual bleeding can genuinely relate to anovulation, where progesterone never rises to oppose estrogen, leaving an unstable lining that sheds heavily. Here, regulating the cycle helps. But heavy bleeding has many other causes, including fibroids, adenomyosis, polyps, clotting disorders, and thyroid disease, that need evaluation. Treating all heavy bleeding as 'low progesterone' misses important diagnoses.

Infertility blamed on low progesterone is more nuanced. In women who don't ovulate, the issue isn't progesterone deficiency itself but the absence of ovulation, so treatment focuses on ovulation induction. In ovulatory women with unexplained infertility, routine progesterone hasn't been shown to help on its own.

Weight gain, hair loss, mood swings, and low libido are frequently attributed to low progesterone in adverts for creams and supplements. The evidence for progesterone deficiency causing these in cycling women is generally weak. These symptoms have many causes (thyroid disease, PCOS, perimenopause, depression, nutritional deficiency, stress, medications) that deserve systematic evaluation. Over-the-counter progesterone creams have particularly weak evidence and inconsistent dosing, and FOGSI and the Indian Medical Association have cautioned against unsupervised use.

Testing correctly is the whole game. The standard test is a serum progesterone drawn about 7 days after you ovulate, often called 'day 21 progesterone' for a textbook 28-day cycle, because it aims to catch the mid-luteal peak. If your cycle is longer or shorter than 28 days, the timing must shift: test about 7 days before your next expected period, regardless of the day number.

In India, progesterone testing is widely available at chain labs (SRL, Metropolis, Dr Lal PathLabs, Thyrocare) for roughly Rs 400 to Rs 800, with results in 24 to 48 hours. A mid-luteal value above 10 ng/mL generally confirms ovulation; below 3 ng/mL suggests Anovulation Symptoms: Signs You're Not Ovulating; values between 3 and 10 ng/mL are intermediate and may reflect suboptimal luteal function or, very often, mistimed testing.

One reading has real limits. Progesterone is released in pulses, so a single low value can simply be a trough between pulses rather than a true deficiency. For a closer look at luteal function, some clinicians take three measurements across the luteal phase or pool samples, though for most purposes a single, correctly timed value is enough to confirm or rule out ovulation.

Urinary progesterone metabolite testing (pregnanediol glucuronide, or PdG) using over-the-counter ovulation-confirmation kits is increasingly available, roughly Rs 800 to Rs 2,500 per pack. These measure PdG across several luteal days and are useful for confirming ovulation without blood draws, especially for women trying to conceive. They confirm that ovulation happened but don't quantify progesterone with the precision needed for fertility-treatment monitoring.

Salivary and home capillary progesterone tests, often sold direct-to-consumer alongside 'hormone-balancing' supplements, lack standardisation and validated reference ranges for routine clinical use. Treat their results cautiously and ideally with a clinician who understands their limits; they are not equivalent to standard serum testing.

Above all, test to answer a specific question. Appropriate reasons include suspected anovulation, irregular cycles, suspected LPD in recurrent loss, monitoring ovulation induction or IVF, and confirming ovulation when trying to conceive. Testing vague symptoms with no hypothesis, screening women with no symptoms, or testing progesterone while on combined hormonal contraception (which suppresses ovulation, so it's expected to be low) is misleading.

Progesterone is essential for maintaining early pregnancy. The corpus luteum supplies it for the first 8 to 10 weeks, then the placenta takes over with steadily rising production. Adequate progesterone supports endometrial receptivity at implantation and helps quiet uterine contractions. This central role has led to widespread supplementation across many pregnancy situations, with very different levels of evidence behind each.

Luteal phase support in IVF and other ART cycles is the most evidence-based use. Because stimulation medications disrupt corpus luteum function, exogenous progesterone bridges the gap until placental production takes over. Vaginal progesterone (Susten, Cygest, Crinone) at 200 to 800 mg daily, intramuscular progesterone in oil, or oral dydrogesterone are standard, usually continued until 10 to 12 weeks. This is universal in IVF practice in India and globally.

Threatened miscarriage (early-pregnancy bleeding with a viable fetus on scan) is a context where progesterone is commonly prescribed in India. The PRISM trial (2019) suggested vaginal progesterone modestly improves live-birth rates in women with bleeding plus a history of one or more prior Miscarriage Causes and Risks: An Evidence-Based Guide; the benefit was not seen in women without a prior loss. Typical regimens use micronised vaginal progesterone 200 to 400 mg twice daily through the first trimester, roughly Rs 800 to Rs 2,000 a month.

Recurrent pregnancy loss has been studied extensively. The PROMISE trial (2015) found progesterone did not significantly improve live-birth rates in unexplained recurrent loss overall, though subgroups may benefit. Current FOGSI and ESHRE guidance is cautious: progesterone is reasonable in women with documented LPD or with prior loss plus current bleeding, but is not recommended for all women with recurrent loss.

Preterm-birth prevention has its own evidence base. Vaginal progesterone reduces preterm birth in women found to have a short cervix (under 25 mm) in the second trimester. Intramuscular 17-hydroxyprogesterone caproate, once used for women with a prior preterm birth, was questioned by a large trial, and its US approval was withdrawn in 2023; vaginal progesterone remains the standard for short cervix.

Routine progesterone in an otherwise normal pregnancy is not recommended. Many women in India receive prescriptions in normal early pregnancy without a specific indication, adding cost without clear benefit. It's reasonable to ask your obstetrician for the specific reason rather than accepting a routine prescription without explanation.

Progesterone change is what defines the transition to menopause. As the ovarian follicle reserve declines, ovulation becomes less frequent. Anovulatory cycles produce no luteal progesterone, creating estrogen-dominant patterns even when estrogen itself swings. This 'relative progesterone deficiency' is thought to drive many perimenopausal symptoms, including heavy or prolonged bleeding, breast tenderness, disturbed sleep, mood changes, and anxiety.

Heavy bleeding in perimenopause is a common sign of declining progesterone. Without ovulation, the lining sees unopposed estrogen, thickens, and sheds unpredictably, so periods become heavier, longer, or more irregular. Options include cyclical progestin (medroxyprogesterone or norethindrone for 10 to 12 days a month), the Mirena IUD (continuous local progestin that dramatically cuts bleeding), tranexamic acid for acute episodes, and, if needed, endometrial ablation or hysterectomy. New or persistent heavy bleeding warrants investigation for hyperplasia or polyps, especially with risk factors.

MHT for a woman with an intact uterus requires a progestogen alongside estrogen to protect the lining. Common choices are oral micronised progesterone (Susten, Utrogestan) 100 to 200 mg daily, medroxyprogesterone, dydrogesterone, or the Mirena IUD. Oral micronised progesterone has the bonus of improving sleep when taken at night and a more favourable metabolic profile. For local genitourinary symptoms, vaginal estrogen is a separate, low-dose option. We cover the full picture in hormone therapy in the Indian context and HRT cost and options.

Hot flushes, night sweats, and mood changes relate more to estrogen fluctuation than to progesterone specifically. Combined estrogen-plus-progestogen MHT is the most effective treatment in suitable candidates. Progesterone-only therapy is sometimes used by women who can't or prefer not to take estrogen, with modest benefit; oral micronised progesterone alone may help sleep and some flush severity but is generally less effective than combined therapy.

Bleeding on MHT depends on the regimen. Cyclic MHT produces scheduled withdrawal bleeds and is used in perimenopause and early menopause; continuous combined MHT aims for no bleeding and suits established menopause. Breakthrough bleeding is common in the first 3 to 6 months and usually settles, but persistent or new bleeding warrants evaluation for endometrial pathology, often with ultrasound and biopsy.

Many Indian women ask about 'natural' progesterone creams, wild yam extracts, or compounded bioidentical hormones marketed as safer. The evidence is weak, dosing is unreliable, and these should not be treated as equivalent to regulated preparations. The Indian Menopause Society and FOGSI are particularly concerned that 'bioidentical' implies a safety not supported by evidence. Note that regulated micronised progesterone is itself structurally identical to natural progesterone, but with manufacturing controls that compounded products lack. For non-drug options, see herbal and holistic menopause support.

Treatment with progesterone or a progestin is appropriate in specific scenarios and pointless in others; matching the treatment to the cause is the difference between effective care and wasted expense. The clearly appropriate uses include luteal support in IVF, threatened miscarriage in women with prior loss, preterm-birth prevention with a short cervix, menopause hormone therapy, treatment of endometrial hyperplasia, contraception, and managing abnormal uterine bleeding from anovulation.

Micronised natural progesterone (Susten, Utrogestan, generics) is identical to the body's own and comes as oral, vaginal, and intramuscular forms. Oral capsules (100 to 300 mg) are common in MHT and some pregnancy indications; vaginal forms (Susten vaginal, Cygest) are used for luteal support, threatened miscarriage, and short-cervix preterm prevention; intramuscular progesterone in oil gives higher, more sustained levels in IVF.

Synthetic progestins differ and have varied profiles. Medroxyprogesterone (Provera, Meprate) 5 to 10 mg daily for 10 to 14 days a month induces withdrawal bleeding in anovulation and protects the lining in MHT. Norethindrone (Norlut, Primolut N) is used for cycle regulation and heavy bleeding. Dydrogesterone (Duphaston) 10 mg twice or thrice daily is widely used in India for luteal support, threatened miscarriage, and endometriosis. Costs typically run Rs 100 to Rs 400 per pack.

Hormonal IUDs (Mirena, Kyleena) deliver continuous local levonorgestrel, dramatically reducing menstrual bleeding while providing contraception, and they double as the progestin component of MHT. In India they cost roughly Rs 8,000 to Rs 15,000 plus insertion, lasting 5 to 7 years, and many women become essentially period-free.

Often, non-progesterone treatments work better for symptoms misattributed to 'low progesterone'. For PMS and PMDD, SSRIs, combined hormonal contraceptives, exercise, sleep, and CBT have stronger evidence. For anxiety and insomnia, addressing the underlying cause is more effective. For heavy bleeding, evaluating and treating fibroids, polyps, adenomyosis, or thyroid disease is essential alongside any hormonal approach.

Over-the-counter progesterone creams and supplements sold for 'hormone balance', weight loss, or anti-aging are generally not recommended by FOGSI or the Indian Medical Association. Dosing is unreliable, claims outrun evidence, and the real conditions they claim to fix need specific diagnosis. Money spent on these is usually better spent on a proper evaluation.

• Restore healthy body weight and energy balance to support ovulation
• Manage stress with sustainable routines, not just supplements
• Aim for 7 to 9 hours of consistent sleep and morning daylight
• Choose moderate exercise; avoid heavy training combined with calorie deficit
• Eat a balanced, whole-food Indian diet; limit maida, fried foods, and sugary drinks
• Don't rely on 'progesterone-boosting' supplements in place of evaluation

Many women trying to conceive fixate on progesterone after reading that 'low progesterone' causes failed conception or early miscarriage. The reality is more specific: progesterone matters in fertility, but the issue is usually ovulation rather than deficiency itself, and the most useful steps address ovulation directly.

Confirming ovulation is the first step. A mid-luteal progesterone above 10 ng/mL confirms ovulation; below 3 ng/mL suggests anovulation. Other methods include ovulation predictor kits, basal body temperature charting, and cervical mucus observation. PdG urinary testing also confirms ovulation and luteal function. For women with regular cycles and no other concerns, ovulation can often be assumed. Our guide to tracking ovulation walks through the options.

Anovulation is the commonest ovulatory cause of infertility, most often from PCOS, hypothalamic amenorrhoea, thyroid dysfunction, or high prolactin. Treatment targets the cause: ovulation induction with letrozole (Femara, roughly Rs 200 to Rs 800 a cycle) or clomiphene for PCOS, restored energy balance for hypothalamic amenorrhoea, levothyroxine for hypothyroidism, and cabergoline for high prolactin. Once ovulation returns, progesterone follows naturally; direct supplementation doesn't fix the underlying anovulation.

Luteal phase defect as a primary cause of infertility is controversial. ASRM notes the diagnosis is poorly reproducible and uncommon as a sole cause, and routine progesterone in unexplained infertility hasn't consistently improved outcomes. Some clinicians still use empiric luteal progesterone in selected cases (subjectively short luteal phase or recurrent loss), but this isn't strongly evidence-supported.

In IVF and other ART cycles, luteal progesterone support is standard and evidence-based because stimulation drugs disrupt corpus luteum function. Vaginal progesterone, intramuscular progesterone, or oral dydrogesterone are used through the first trimester. This is distinct from the question of whether progesterone helps in natural conception, where the case is much weaker. For a focused look, see can progesterone help you get pregnant.

Recurrent pregnancy loss (two or more consecutive losses) needs systematic workup, including chromosomal analysis where feasible, parental karyotyping, uterine evaluation, a thrombophilia panel, antiphospholipid antibodies, thyroid function, and HbA1c. Progesterone may help selected subgroups (prior loss plus current bleeding, per PRISM) but is not a universal answer; PROMISE showed no benefit in unexplained recurrent loss overall. Women experiencing repeated loss are better served by evaluation at a fertility or maternal-fetal medicine centre than by empiric progesterone alone.

• No periods for three months or more, fewer than 9 periods a year, cycles consistently over 35 or under 21 days, or a sudden change in pattern: warrants TSH, prolactin, day 2 to 5 FSH/LH, and assessment for PCOS, thyroid disease, high prolactin, or premature ovarian insufficiency.
• Heavy or prolonged bleeding: soaking through a pad or tampon every 1 to 2 hours for several hours, periods longer than 7 days, large clots, or symptoms of anaemia (fatigue, pallor, breathlessness). Investigation includes ultrasound, a complete blood count, ferritin, and TSH.
• Premenstrual symptoms severe enough to disrupt work, relationships, or daily life, especially severe luteal-phase mood symptoms that lift with your period. PMDD is a recognised, treatable diagnosis.
• Trouble conceiving after 12 months of trying (or 6 months if over 35), or two or more pregnancy losses: warrants a structured fertility evaluation rather than empiric progesterone.
• Perimenopausal symptoms (hot flushes, disrupted sleep, mood and cognitive changes) that affect quality of life: effective treatments exist and are worth discussing, ideally at a clinic familiar with menopause care.
• Any postmenopausal bleeding, or new or persistent bleeding on hormone therapy: always needs evaluation to exclude endometrial pathology.

• ACOG: Hormone Therapy and Menopause
• ASRM: The Clinical Relevance of Luteal Phase Deficiency (Committee Opinion)
• Coomarasamy et al., A Randomized Trial of Progesterone in Women with Recurrent Miscarriages (PROMISE), NEJM
• Coomarasamy et al., A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy (PRISM), NEJM
• NICE Guideline NG23: Menopause — diagnosis and management
• ESHRE Guideline: Recurrent Pregnancy Loss
• Indian Menopause Society — Clinical Practice Guidelines